November 1, 2022

Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

Milestone payment to Dragonfly is triggered by dosing of first patient in Phase 1 clinical trial Dragonfly Therapeutics, Inc....

March 31, 2022

Dragonfly Therapeutics Expands Clinical Leadership Team

Appointing Dr. Hesham Aboshady as Head of Safety & Pharmacovigilance and Rajesh Israni as Head of Regulatory Affairs. Hesham Aboshady MD,...

November 24, 2021

Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

The dragon is flying high today as Merck hits go on a second immunotherapy candidate from its $700 million pact with Dragonfly...

November 23, 2021

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients

Merck executes option to license its second immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets....

January 12, 2021

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.

December 2, 2020

Merck opts in for Dragonfly's TriNKET cancer immunotherapy program

The U.S. Big Pharma is getting its hands on its first TriNKET immunotherapy candidate from the biotech, which comes after the pair...

August 18, 2020

Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy

Bristol Myers Squibb is paying nearly half a billion dollars in up front and near-term payments to license an early-stage immunotherapy...

August 17, 2020

Bristol Myers Squibb pens $475M Dragonfly pact for IL-12 program

By Ben Adams Bristol Myers Squibb is paying nearly half a billion in near-term and upfronts to licence Dragonfly Therapeutics’...

July 7, 2020

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

Bristol Myers Squibb likes what it sees from the immune cell research of Dragonfly Therapeutics so far—enough to pay $55 million to add...

March 19, 2020

Doing deals in a time of coronavirus

Biotech CEO Bill Haney says 'you focus on the things that make a difference' Fidelity Management and Research has led a new round for...

November 12, 2019

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2...

October 1, 2018

Merck & Co. Partners with Dragonfly on NK-Based Cancer Immunotherapies

Merck & Co. plans to develop new solid tumor cancer immunotherapies using Dragonfly Therapeutics’ Tri-specific NK cell Engagement...

May 2, 2022

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engage

Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of...

March 1, 2022

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk,...

November 24, 2021

Merck hits 'go' on a second Dragonfly drug

Merck & Co. Inc. has decided to move forward on its option to license a second drug from Waltham-based Dragonfly Therapeutics. The two...

November 9, 2021

Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

The company announces that its lead TriNKET™ immunotherapy program DF1001, a HER2-targeted NK cell engager therapy...

January 12, 2021

AbbVie selects target for Dragonfly partnership

Dragonfly’s partnership with AbbVie is beginning to bear fruit.

December 1, 2020

Merck’s Roger Perlmutter buys his first solid tumor TriNKET from Dragonfly

A little more than 2 years after Merck’s Roger Perlmutter signed off on a deal that would pay Dragonfly up to $695 million for each drug...

August 18, 2020

Aiming for immunotherapy boost, Bristol Myers deepens ties with Dragonfly

Dive Brief: Bristol Myers Squibb has licensed from privately held biotech Dragonfly Therapeutics an experimental immunotherapy that it...

August 17, 2020

Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology

With a potential IL-12 game-changer This morning Bristol Myers R&D maestro Rupert Vessey is taking the wraps off one of the biggest cash...

July 6, 2020

A booming Dragonfly is taking its TriNKETs to Copenhagen

As the latest Bristol Myers pact spurs expansion plans -- outside the US Bristol Myers Squibb is making a habit out of collaborating with...

November 20, 2019

AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player

Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly...

October 2, 2018

Dragonfly Therapeutics in $695M cancer R&D pact with Merck

More than a year after insect-inspired biotech Dragonfly Therapeutics penned a blood cancer pact with big biotech Celgene, it's back at...

October 1, 2018

Dragonfly and Merck Strike $695 Million Deal for Solid Tumors

Waltham, Mass.-based Dragonfly Therapeutics struck a licensing agreement worth up to $695 million with Merck. Merck will license...

April 21, 2022

Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie

Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in...

November 24, 2021

Merck and Dragonfly, Together Again

This morning, investors in privately-held Dragonfly Therapeutics are thankful after Merck opted to license its second TriNKET...

November 23, 2021

Dragonfly gets Merck on second TriNKET candidate since 2018 collab

Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET platform. First Celgene, then BMS, and now Merck —...

October 18, 2021

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb

The company announces its sixth drug licensed by Bristol Myers Squibb, and the first patients enrolled and dosed in Phase 1 clinical...

December 10, 2020

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

In the second year of Endpoints News’  budding tradition of highlighting women blazing trails in biopharma R&D, we’ve seen a number of...

November 24, 2020

Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer

and also Strengthens Scientific Advisory Board WALTHAM, Mass., Nov. 24, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or...

August 17, 2020

Dragonfly Therapeutics and Bristol Myers Squibb Announce Exclusive Global License

For Dragonfly’s IL-12 Investigational Immunotherapy Program Agreement Includes DF6002, With Potential to Advance Treatment of Solid...

August 10, 2020

Dragonfly Therapeutics Announces BMS Opt-In of Fourth TriNKET™ Immunotherapy Drug Candidate

Published: Aug 10, 2020 WALTHAM, Mass., Aug. 10, 2020 /PRNewswire/ -- Dragonfly Therapeutics, Inc.. ("Dragonfly" or the "Company"), today...

May 11, 2020

Dragonfly Therapeutics Appoints Head of Clinical Development

Published: May 11, 2020 Tapan Maniar M.D. with 10+ years of biotech and pharma experience has been appointed head of clinical development...

November 13, 2019

Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors

WALTHAM, Mass., Nov. 12, 2019 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel...

October 2, 2018

Merck’s cancer R&D juggernaut ties up to little Dragonfly’s natural born killer platform

with billions on the line A little more than a year after Celgene bellied up to the partnership table with $33 million in cash to ally...

January 10, 2018

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

by John Carroll Editor & Founder of ENDPOINTS Over the last 15 years I’ve had the chance to help select about 200 private biotechs for...